Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

vintage textured collage with symbols of New York City

Tariffs

Biotech’s Next Phase Will Be All-American: Pitchbook

With tariffs pushing manufacturing home to the U.S., Pitchbook warns of reduced M&A activity and venture capital funding.

April 17, 2025

2 min read

Annalee Armstrong

Closeup of businessman give money to robot. Man pass banknote bribe to robotic assistant. AI and technology. Vector illustration.

Artificial intelligence

Sanofi Bets More Than $1.8 Billion in Biobucks on AI-Developed Bispecifics

The French pharma giant has made multiple trips to the artificial intelligence well over the past few years, this time with Delaware-based Earendial Labs.

April 17, 2025

2 min read

Dan Samorodnitsky

ASD autism neurodevelopmental spectrum disorder, deficits in social communication and interaction, brain with impairment, hypersensitivity and abnormalities

Editorial

Kennedy’s Hunt for a Connection Between Vaccines and Autism Is a Sham

The Health and Human Services Secretary said that he will find and eliminate the cause of autism by September, an idea that suggests how little he knows about the condition.

April 17, 2025

3 min read

Dan Samorodnitsky

Profit and Money Concept, Financial and Business Graph

GLP-1

Lilly Skyrockets on ‘Injectable-Like Efficacy’ for Oral GLP-1 in Phase III Diabetes Trial

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a late-stage study in type 2 diabetes, eliciting significant reductions in body weight and improvements in glucose control.

April 17, 2025

2 min read

Tristan Manalac

Vaccines

HHS Pulls Funding for GeoVax’s Next-Gen COVID-19 Vaccine

GeoVax was using its HHS contract to develop its next-generation multi-antigen COVID-19 vaccine, which is in Phase IIb development.

April 17, 2025

2 min read

Tristan Manalac

Entrance to the U.S. Department of Health and Human Services in Washington, DC

Government

Trump Eyes $40 Billion Budget Cut for HHS: Reports

Despite these cuts, the FDA should be able to stay above a “trigger” level that would prevent it from collecting fees from the pharma industry and deprive it of approximately half of its annual funding, according to The Washington Post.

April 17, 2025

2 min read

Tristan Manalac

Policy

RFK Jr. Eyes Changes to Vaccines Injury Surveillance System to Deduce ‘Culprit’

Kennedy is planning modifications to the Vaccines Adverse Event Reporting System to identify whether vaccines contribute to an unstated problem. The reporting system is at the heart of the departure of CBER head Peter Marks.

April 17, 2025

2 min read

Tristan Manalac

Illustration of employee replacement concept with one employee leaving and another trying to get a job

Layoffs

Q1 Biopharma Layoffs Hit California, Massachusetts Hard

During the first quarter, 22 rounds of biopharma layoffs in California affected about 995 employees total, while 17 rounds in Massachusetts impacted around 410 people, based on BioSpace estimates. Meanwhile, competition for jobs in those states increased year over year, according to BioSpace data.

April 17, 2025

5 min read

Angela Gabriel